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There are no specific signs and symtoms for invasive candidiasis (IC), which makes
its diagnosis a challenge. Efforts have been made for decades to establish serological
assays for rapid diagnosis of IC, but none of them have found widespread clinical use.
Using a systemic candiasis murine model, serological response to recombinant proteins
of enolase (rEno1), phosphoglycerate kinase (rPgk1), and β-glucosidase (rBgl2) were
evaluated and rEno1 was found to possess the strongest immunoreactivity, followed
by rPgk1 and rBgl2. Likewise, IgG antibody titers to rEno1, rPgk1, and rBgl2 in the
positive sera of proven IC patients were determined by ELISA. Results show anti-rEno1
antibody possesses the highest titer, followed by rPgk1 and rBgl2. Antibodies against
rEno1, rPgk1, and rBgl2 were detected by ELISA tests in a group of 52 proven IC
patients or 50 healthy subjects, The sensitivity, specificity, positive and negative predictive
values were 88.5, 90.0, 90.2, and 88.2% for anti-rEno1 detection, 86.5, 92.0, 91.8, and
86.8% for anti-rPgk1 detection, and 80.8, 90.0, 89.4, and 81.8% for anti-rBgl2 detection,
respectively. The data clearly demonstrate that the recombinant proteins of Eno1, Pgk1,
and Bgl2 are promising candidates for IC serodiagnosis. There’s great possibility that
the recombinant Eno1 will be more applicable in serodiagnosis and vaccine research on
account of its strong serological response.
Keywords: invasive candidiasis, serodiagnosis, serological response, enolase, phosphoglycerate kinase,
β-glucosidase
Introduction
Invasive candidiasis (IC) continues to be a life-threatening infectious disease affecting an ever-
increasing number of hospitalized patients and, of particular concern, causing considerably high
morbidity and mortality. In the USA, Candida species is among the five major pathogens leading
to nosocomial blood stream infections (BSIs) and causing 8–10% of nosocomial BSIs (Pappas, 2006;
Pfaller and Diekema, 2007; Morrissey, 2013; Sievert et al., 2013). Though a variety of Candida
species can produce invasive infection, Candida albicans (C. albicans) continues to be identified
as a leading pathogen. The risk of candidiasis is increased by some factors mainly including
broad-spectrum antibacterial therapy, intense myelosuppression, and cytotoxic therapies,
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recent gastrointestinal surgery and the presence of central venous
access devices (Pappas, 2006).
The identification of patients at risk of IC is complicated in
that there are usually no specific clinical signs and symptoms.
Recovery of Candida species from blood specimen is considered
as the standard method for candidemia diagnosis. However, the
low sensitivity (approximately 50%) and positive results may
appear only in the advanced stage of infection which dramatically
hampers its role in clinical practice (Yera et al., 2001). Though
the germ tube test has been performed successfully on samples
collected directly from positive blood cultures, rather than
waiting for Candida colonies to grow on agar plates (Terlecka
et al., 2007; Sheppard et al., 2008), the long duration is still an
overwhelming disadvantage of blood culture.
Efforts have been made for decades to establish serological
diagnosis assay to identify IC patients. Detection of antigens from
the infecting agent in host’s samples is considered as one of the
practical strategies. These antigenic molecules mainly include
(1,3)-D-glucan (BDG) (Ostrosky-Zeichner et al., 2005; Pickering
et al., 2005; Cuetara et al., 2009), galactomannan (Sendid et al.,
1999), enolase (Walsh et al., 1991), aspartyl proteinase (Morrison
et al., 2003), andD-arabinitol (Christensson et al., 1999; Yeo et al.,
2000). Serological tests detecting candida cell wall components,
such as galactomannan and BDG, have become widely used
diagnostic tools and commercially available. Antigen detection
has the advantage of high specificity but often lack the desired
level of sensitivity required for a definitive diagnosis. The main
reason for this may be that most of the circulation pathogen
antigens are usually cleared out from the blood circulation
rapidly since the occurrence of infection. In addition, false
positive results may occur in antigen-based detection test because
of the contaminants in sample preparations or patients suffering
from certain bacterial infections (Hope et al., 2005; Mennink-
Kersten et al., 2008).
Consideration of patient’s antibody response provides another
option for IC diagnosis. Eno1, Pgk1, and Bgl2 are well-
documented proteins located on the cell surface of C. albicans.
These proteins possess high conservation during species
evolution and their loose association with the cell wall might
facilitate the production of antibodies by C. albicans-infected
hosts (Montagnoli et al., 2004; Pitarch et al., 2004, 2006).
Based on immunoproteomic approach using two-dimensional
electrophoresis followed by quantitative Western blotting and
mass spectrometry, Pitarch et al. (2006) demonstrated that Eno1,
Pgk1, and Bgl2 were the independent predictors of systemic
candidiasis (SC) and valuable candidates for future vaccine
development. These enzymes show strong antibody response
to the SC patients’ sera, even in the immunocompromised
hosts.
In the present study, we evaluate the immunoreactivity of
recombinant C. albicans proteins of Eno1 (rEno1), Pgk1 (rPgk1),
and Bgl2 (rBgl2) by a systemic candiasis murine model. We also
report the serodiagnosis of infection by invasive Candida species
using ELISA to detect specific antibodies against rEno1, rPgk1,
and rBgl2. The objective of this study is to explore the potential
use of rEno1, rPgk1, and rBgl2 in the diagnosis of IC to further
expand our knowledge of IC control.
Materials and Methods
Candida Strain and Growth Conditions
C. albicans strain SC5314 was routinely grown in YPD medium
(1% yeast extract, 2% peptone, 2%D-glucose) at 35◦C, 5% CO2.
Study Population and Serum Specimens
All patients were admitted to the Bethune International Peace
Hospital, Shijiazhuang, China, from October 2011 to December
2013. Following the criteria made by the European Organization
for the Research and Treatment of Cancer/Mycoses Study Group
[EORTC/MSG] (Ascioglu et al., 2002), the 102 subjects enrolled
in this study were classified to two groups: proven IC patients
group (n = 52) and control individuals (n = 50). For proven IC
subjects, the serum samples were obtained retrospectively within
24 h after positive culture results, which assured uniformity and
that all subjects had active disease at the time of enrollment.
To provide data on assay specificity, the control individuals had
similar age and sex distribution to the proven IC patients. Serum
was separated, aliquoted, and stored at 2 ∼ 8◦C for up to 48 h or
frozen at−80◦C until tested.
The study protocol was approved by the Ethics Committee
of Bethune International Peace Hospital and informed consent
was obtained from all patients included in the study. All sera
were analyzed in a blinded fashion. Data including age, primary
condition, and clinical stage were obtained from the clinical
records. Base-line characteristics of the proven IC patients are
shown in Table 1.
Generation of Recombinant Eno1, Pgk1, and Bgl2
As is shown in Table 2, primers were designed to clone
and express full length protein with the software of Primer
Premier 5.0. PCR products were cloned into the pET-30a (+)
expression vector (Merckmillipore, Germany). All inserts were
confirmed by DNA sequencing. The plasmids were transformed
into Escherichia coli BL21 (DE3) competent cells (Transgen
Biotech, Beijing, China). Expression of recombinant antigens was
induced by isopropyl-β-D-thiogalactopyranoside (IPTG). His6-
tagged recombinant proteins were confirmed by 12% SDS-PAGE.
Recombinant antigens were purified from cell-free supernatants
by chromatography on Ni2+ nitrilotriacetic acid-agarose (His-
trap HP) in accordance with the manufacturer’s instructions (GE
Healthcare, USA).
Triton X-114 liquid phase separation was carried out to
remove the contaminated endotoxin (LPS) in the recombinant
proteins. The recombinant protein solutions (1mL) were mixed
with 100µL 10% (w/v) Triton X-114 (sigma) by vigorous
vortexing. The mixtures were placed in an ice bath for 10min
to ensure a homologous solution. After vortexing, the samples
were incubated at 37◦C for 10min to form the two phases. Then,
the samples were centrifuged for 1min with a microcentrifuge at
25◦C in an incubator. Fractions containing purified recombinant
proteins were pooled, dialyzed against PBS and stored at−80◦C.
Murine Model of Systemic Candidiasis
Specific pathogen free (SPF) BALB/c female mice weighing
from 18 ∼ 20 g (Vital River, China) were chosen to establish
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TABLE 1 | Base-line characteristics of the 52 patients with invasive candidiasis included in the study.
Patient No. Sexa Age Hospital ward Underlying condition Site of Candida isolationb Isolated Candida
1 F 77 Respiratory Pneumonia Blood C. albicans
2 M 93 Respiratory Pneumonia; Cardiac carcinoma Blood C. albicans
3 F 33 Surgery Acute pancreatitis Blood C. tropicalis
4 M 72 ICU Gastric carcinoma; Acute peritonitis Blood C. glabrata
5 M 80 Respiratory Pneumonia Blood C. tropicalis/
C. parapsilosis
6 M 66 ICU Intestinal obstruction Blood C. albicans
7 M 79 Cardiology Coronary heart disease Blood C. glabrata
8 M 81 ICU Cardiac carcinoma Blood C. tropicalis
9 M 87 Respiratory Chronic bronchitis Blood C. lusitaniae
10 M 72 Hematology Chronic myelocytic leukemia Blood C. albicans
11 M 84 Endocrinology Diabetes Blood C. krusei
12 F 34 ICU Septic shock Blood C. albicans
13 M 31 ICU Septic shock Blood C. albicans
14 M 70 Respiratory Respiratory failure Blood C. lusitaniae
15 M 88 Respiratory Respiratory failure Blood C. krusei
16 M 61 ICU Adenocarcinoma Blood C. parapsilosis
17 M 31 Burns unit Burns Blood C. albicans
18 F 85 Surgery Colorectal carcinoma Blood C. albicans
19 F 81 ICU Blood C. glabrata
20 F 64 Infectious disease Hepatic Cirrhosis Blood C. glabrata
21 F 52 ICU Asthma Blood C. albicans
22 M 72 Respiratory Pneumonia Blood C. krusei
23 M 26 ICU Septic shock Blood C. albicans
24 M 28 Burns unit Burns Blood C. albicans
25 M 81 ICU Cardiac carcinoma Blood C. tropicalis
26 M 73 ICU Gastric carcinoma Blood C. tropicalis
27 M 52 Burns unit Burns Blood C. tropicalis
28 F 49 ICU Multiple organ failure Blood C. tropicalis
29 M 58 Surgery Surgery Blood C. glabrata
30 M 62 Surgery Small intestine fistula Blood C. parapsilosis
31 M 73 Respiratory Pneumonia Blood C. albicans
32 M 64 ICU Gastric carcinoma Blood C. tropicalis
33 F 41 Hematology Leukemia Blood C. albicans
34 F 29 Respiratory Respiratory failure Blood C. parapsilosis
35 F 58 Surgery Cardiac carcinoma Ascites C. albicans
36 M 32 Surgery Acute pancreatitis Ascites C. parapsilosis
37 M 38 Surgery Peritonitis Ascites C. albicans
38 F 61 Surgery Colorectal carcinoma Ascites C. parapsilosis
39 M 31 ICU Abdomen trauma Ascites C. tropicalis
40 M 21 ICU Abdominal stab wound Ascites C. parapsilosis
41 M 75 ICU Peritonitis Ascites C. albicans
42 F 61 Respiratory Cardiac carcinoma Ascites C. glabrata
43 F 59 Respiratory Abdominal stab wound Ascites C. parapsilosis
44 M 69 Surgery Peritonitis Ascites C. glabrata
45 F 32 Surgery Peritonitis Ascites C. albicans
46 M 82 Surgery Small intestine carcinoma PL C. parapsilosis
47 F 63 Surgery Esophageal cancer PL C. albicans
48 M 88 Digestive disease Gastric carcinoma PL C. albicans
49 F 52 Surgery Right shoulder arthritis JF C. guilliermondii
50 F 82 Respiratory Pneumonia JF C. albicans
51 F 60 Surgery Craniocerebral trauma CSF C. albicans
52 M 85 Surgery Subarachnoid hemorrhage CSF C. albicans
aM, male; F, female.
bPL, pleural liquid; JF, joint fluid; BALF, bronchoalveolar lavage fluid; CSF, cerebrospinal fluid.
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TABLE 2 | Oligonucleotide primer sequences used in this study.
Primera Genebank accession No. Sequenceb (5′ - 3′) Restriction enzyme
Eno1_F NW_139596 CCGGATCCATGTCTTACGCCACTAAAATC BamH I
Eno1_R GCCTCGAGTTACAATTGAGAAGCCTTTTG Xhol I
Pgk1_F NW_139621 GCGGATCCTCATTATCTAACAAATT BamH I
Pgk1_R TACTCGAGGTTTTTGTTGGAAAGA Xhol I
Bgl2_F NW_139425 AAGGATCCATGCAAATCAAATTCTTGAC BamH I
Bgl2_R CGCTCGAGTTAGTTGAATTTACAGTCAA Xhol I
aEno, enolase; Pgk, phosphoglycerate kinase; Bgl, β-glucosidase; F, forward; R, reverse;
bUnderlined, restriction sites.
the murine model of SC. Animal welfare and experimental
procedures were approved by the Bethune International Peace
Hospital Animal Care and Use Committee. Protocols were
conducted in strict accordance with the Guide for the Care and
Use of Laboratory Animals (National Research Council (US)
Institute for Laboratory Animal Research, 1996). Efforts were
made to minimize the animals used and their suffering. Before
the pathogen challenge, mice were injected intraperitoneally
(i.p.) with Cyclophosphamide (Jiangsu Hengrui Medicine Co.,
Ltd., China) at a dose of 100mg/kg. Four days later, mice
were injected i.p. with a dose of 1 × 106 CFU of C. albicans
SC5314 (in 0.1mL) or an equivalent amount of sterile saline
as control. Three randomly chosen mice from each group were
humanely sacrificed on the day of 0, 1, 2, 4, 6, 8, 12, 16, 20, 24,
and 30 after pathogen administration. Blood was collected by
cardiac puncture and was allowed to clot on ice. The serum was
separated from the clot by centrifugation and stored at −80◦C.
Pathogen loads in kidney, lung, liver, and spleen of infected
mice were determined (homogenized in saline) at different time
points during the course of infection. Kidneys were dissected
and processed to histological analysis (formalin fixed).
Preparation of C. albicans Protein Extract
Yeast cells were harvested and washed with pre-cold sterile saline
and then incubated at 30◦C in a solution containing 30 g/ml
Glusulase (sigma), 1M sorbitol and 1% 2-mercaptoethanol (up to
5× 108 cells/ml) until over 90% protoplasts were obtained. After
a vigorous vortexing and adding 1mM PMSF, an ultrasonication
process was conducted to disrupt the protoplasts. The mixture
was centrifuged at 4◦C and the supernatant was sterile filtered
(0.2-mm pore) to remove residual debris and intact cells.
ELISA Assay
Preliminary checkerboard titration experiments were performed
to determine the optimal concentration of antigen by comparing
the known positive and negative human sera.
For measuring the serum antibody titers of SC mice, rEno1,
rPgk1, rBgl2 were used to coat 96-well microtiter plates (JET
BIOFIL, China). Protein extract of C. albicans was used as
positive control, and protein extract of E. coli and BSA were
used as negative controls. The concentrations of these proteins
were adjusted to 500 ng/mL before use. Unbound antigens were
removed by washing with PBS-T (PBS containing 0.05% Tween-
20). The wells were blocked with 3% BSA/PBS-T over night at
4◦C. Serial two-fold diluted sera of mice were used as the test
antibody, and peroxidise conjugate goat anti-mouse antibody
(1:10,000 diluted) was used as the secondary antibody. Titers
were defined as the highest serum dilution with a positive result.
For probing with human serum, wells of microtiter plates
were coated, blocked and washed as described above. Pre-diluted
human sera (1:400 for anti-rEno1 probing, 1:200 for anti-rPgk1
probing and 1:100 for anti-rBgl2 probing) was added to the
plates and 1:10,000 diluted peroxidise conjugate goat anti-human
antibody was used as the secondary antibody. The antibody titers
of proven IC patients were determined by using serial 10-fold
diluted sera as the test antibody.
After incubation and washing, 3′, 3′, 5′, 5′-
Tetramethylbenzidine (TMB) was added into the wells as
the substrate solution. After 10min of incubation at 37◦C, the
reaction was terminated with 2 N H2SO4, and the microplates
were read at a wavelength of 450 nm using an ELISA reader
(VersaMax plate reader, Molecular Devices Co.).
Western Blot
The recombinant proteins of rEno1, rPgk1, and rBgl2 were
transferred to PVDFmembrane (merckmillipore, Germany) after
12% SDS-PAGE electrophoresis. Membrane was blocked with
Tris buffer (pH 7.5) containing 3% BSA. Next, a 1:400 diluted
mice sera mixture, which was 1:1 blended from the collection
on the 20th and 24th day after C. albicans administration, was
incubated with themembrane at room temperature for 1 h. Then,
the membrane was incubated with peroxidase-conjugated goat
anti-mouse IgG (1/10000). Western blot was developed using
dianilinobenzene (DAB) substrate (Solarbio, China).
Statistical Analysis
All data are given as mean plus or minus SD. Statistical
significance of differences was assessed with Student’s t-tests,
with a P < 0.05 considered to indicate statistically significant
differences. Sensitivity of diagnostic techniques was calculated
from proven IC cases. Specificity was calculated from control
group. Statistical analysis was performed using GraphPad
Prism 5.0.
Results
Generation of Recombinant Protein
For purification of rEno1, rPgk1, and rBgl2, E. coli cells were
lysed, and the extracts were subjected to centrifugation to obtain
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soluble supernatants and pellet fractions. The recombinant
proteins were mainly contained in the soluble fraction and
purified from this fraction by affinity chromatography using an
agarose/Ni-nitrilotriacetic acid column as described in Section
Materials and Methods. As expected, the eluted proteins show
single bands at the expected molecular mass (Eno1 = 48 kDa,
Pgk1 = 46 kDa, and Bgl2 = 33–37 kDa) (Pitarch et al., 2006)
on SDS/PAGE (Figure 1A). The identity of the proteins was
further established by Western blotting using HRP-labeled 6 ×
Hismonoclonal antibody (Figure 1B). The recombinant proteins
were made LPS-free (< 5 EU/mL) by the method of Triton X-114
liquid phase separation.
Establishment of the Murine Model of Systemic
Candidiasis
Within 6 h after C. albicans SC5314 administration, the mice
show typical symptoms of infection including sweat, physical
inactivity compared with the control mice. These infectious
symptoms fade away about 4 days later. Since the kidneys are
reported as the most heavily colonized organs in the mouse
intravenous challenge model (Spellberg et al., 2005; MacCallum,
2009), we chose this organ as an indicator of the mouse
intraperitoneal challenge model for successful infection in the
present study. The kidneys ofC. albicans-infectedmice contained
filamentous fungal cells which were associated with leukocyte
infiltrates (Figure 2A), but there was no evidence of fungal cells
or immune cell infiltrates (Figure 2B) in the kidneys from the
control mice. Peritoneal fluid was used for smear and the growth
FIGURE 1 | SDS-PAGE and Western-blot identification of recombinant
Eno1, Bgl2, and Pgk1. (A) SDS-PAGE identification. Lanes: 1, pET30a-Pgk1
in E. coli BL21; 2, pET30a-Pgk1 in E. coli BL21, induced by IPTG; 3, purified
recombinant Pgk1(46 kDa); 4, pET30a-Bgl2 in E. coli BL21; 5, pET30a-Bgl2 in
E. coli BL21, induced by IPTG; 6, purified recombinant Bgl2(33–37 kDa); 7,
pET30a-Eno1 in E. coli BL21; 8, pET30a-Eno1 in E. coli BL21, induced by
IPTG; 9, purified recombinant Eno1(47 kDa). Molecular markers (in kDa) of
standard proteins are to the left. (B) Identity the recombinant Pgk1(lane 1),
Bgl2(lane 2), and Eno1(lane 3) by Western blotting using peroxidise
-conjugated 6 × His monoclonal antibody, Molecular markers (in kDa) of
standard proteins are to the left.
of fungal hyphae could be easily found under a microscope
(Figure 2C). The fungal densities in kidney, lung, liver, and
spleen of infected mice at different time points are presented in
Figure 2D. The number of fungal colonies gradually increases
from the 1st day after Candida administration. On the 4th day,
the fungal loads in the vital organs reached their peaks and then
gradually decreased. On the 12th day, the fungi ceased to exist
in the lung, liver, and spleen, and the fungal load in kidney was
dropped to 11± 5 CFU/g tissues.
Serological Response to rEno1, rPgk1, and rBgl2
To investigate the serological response of C. albicans infected
mice to rEno1, rPgk1, and rBgl2, the kinetic changes of IgG
antibody titers to the recombinant proteins were measured by
ELISA assay. Experimental results show that the mice with SC
can effectively generate IgG antibodies against rEno1, rPgk1, and
rBgl2 (Figure 3A). On the 6th day post infection, antibodies
against rEno1, rPgk1, and rBgl2 can be detected in the mice sera
and the antibody titers increasing gradually over time. Antibody
titers to rEno1, rPgk1, and rBgl2 reached their peak on the day of
20, 24, and 16 post infection and then slightly dropped down. The
highest titer is about 1:32,768 (1:215) for rEno1, 1:8192 (1:213) for
rPgk1 and 1:4096 (1:212) for rBgl2.
Using the mixed mice sera collected from the 20th and 24th
day post infection as the first antibody, immunoblotting analysis
shows similar results compared with those from the ELISA
tests. The recombinant protein rEno1 was found to possess
the strongest immuno-reactivity, followed by rPgk1 and rBgl2
(Figure 3B).
FIGURE 2 | The murine model of systemic candidiasis. Mice were
injected i.p. with a dose of 1× 106 CFU of C. albicans SC5314 or sterile saline
as control. On the day of 0, 1, 2, 4, 6, 8, 12, 16, 20, 24, and 30 post
infections, three mice of each group were randomly chosen and sampled.
Disease progression was measured in terms of vital organ burdens and kidney
histopathology. Fungal cells (arrowheads) are obvious in the kidneys of mice
infected with C. albicans SC5314 (A), and control kidneys showed no
evidence of fungal cells or immune cell infiltrates (B). Fungal hyphae can be
observed in peritoneal fluid of infected mice (C). Scale bar represents 100mm.
The vital organ fungal burdens reached their peak on the 4th day and ceased
to exist on the 12th day post infection (D).
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FIGURE 3 | Serological response of C. albicans infected mice to
recombinant protein Eno1, Pgk1, and Bgl2. (A) The kinetics of IgG
antibody titers to rEno1, rPgk1, and rBgl2 were measured by ELISA, mice sera
were 1:100 pre-diluted before detection. Protein extract of C. albicans was
used as positive control, and protein extract of E. coli and BSA were used as
negative controls. (B) Using the mixed mice sera collected from the 20th and
24th day post infection as the first antibody (1:400 pre-diluted), Western-blot
show rEno1 possess the strongest immunoreactivity, followed by rPgk1 and
rBgl2.
Detection of IgG Antibodies in Human Sera
Figure 4 shows the results obtained with the serum specimens
drawn from the 52 patients and 50 control subjects who were
tested by ELISA for the detection of IgG antibodies. The median
of anti-rEno1 antibody absorbance for sera from proven IC
patients (median 0.755; interquartile range, 0.527–0.897) was
significantly higher than that from control individuals (median
0.306; interquartile range, 0.254–0.355; P < 0.001) (Figure 4A).
Likewise, proven IC patients had a greater prevalence of
seropositive anti-rPgk1 antibody (median 0.715; interquartile
range, 0.613–0.954) than control individuals (median 0.313;
interquartile range, 0.256–0.392; P = 0.001) (Figure 4B). For
rBgl2, there is also a higher antibody absorbance in proven IC
patients (median 0.721; interquartile range, 0.557–0.893) than
in control individuals(median 0.398; interquartile range, 0.320–
0.468; P < 0.001) (Figure 4C). The cut-off values for serum anti-
rEno1, anti-rPgk1, and anti-rBgl2 were set by receiver operating
characteristic (ROC) curves with A = 0.436 for anti-rEno1,
A = 0.537 for anti-rPgk1, and A = 0.529 for anti-rBgl2.
A patient serum was regarded as positive when ELISA result
was above the cut-off point. As is shown in Table 3, there is
the sensitivity, specificity, and positive and negative predictive
values (PPV and NPV) calculated per patient for the anti-
rEno1, anti-rPgk1, and anti-rBgl2 antibody detection tests.When
the cutoff values mentioned above were used, the sensitivity,
specificity, PPV, and NPV were 88.5, 90.0, 90.2, and 88.2% for
anti-rEno1 detection, 86.5, 92.0, 91.8, and 86.8% for anti-rPgk1
detection, and 80.8, 90.0, 89.4, and 81.8% for anti-rBgl2 detection,
respectively. Serological and microbiological surveillance of
proven IC patients are reported in Table 4.
In this study, IgG antibody titers to rEno1, rPgk1, and rBgl2 in
the positive sera of proven IC patients were determined by ELISA.
As was observed in the systematic infection murine model, anti-
rEno1 antibody possesses the significant higher Ln titer than anti-
rPgk1 (6.90 ± 0.98 vs. 6.12 ± 0.58; P < 0.001) or anti-rBgl2
(6.90± 0.98 vs. 5.53± 0.50; P < 0.001), and anti-rPgk1 antibody
Ln titer is significantly higher (P = 0.001) than anti-rBgl2
(Figure 4D).
Discussion
There is an increasing interest in the development of new,
reliable, and simple diagnostic tests for the diagnosis of IC. It
has been demonstrated that detection of antibodies against cell
wall antigens has diagnostic potency for IC (Clancy et al., 2008;
Li et al., 2013).
In the present study, we generated recombinant proteins of
three cell wall proteins, Eno1, Pkg1, and Bgl2, from C. albicans
SC5314. By using rEno1, rPgk1, and rBgl2 as the antigens, we
developed an indirect ELISA assay to detect the IgG antibodies
against them and ELISA specificity was confirmed by block assay.
Results revealed that recombinant antigens of Eno1, Pgk1, and
Bgl2 from C. albicans reacted to sera from proven IC patients
infected with C. albicans and other Candida species including
C. tropicalis, C. parapsilosis, C. glabrata, C. lusitaniae, C. krusei,
and C. guilliermondii. Several studies have achieved promising
results in the diagnostic utility of the detection of antibodies
against rEno1 (Laín et al., 2007; Clancy et al., 2008; Pitarch et al.,
2008; Li et al., 2013). In 2006, Bgl2 and Pgk1 were described as
novel antigens for SC dianosis (Pitarch et al., 2006). According
to a report from Clancy et al. (2008) about antibody responses
against 15 recombinant antigens from 12 proteins, IgG titers
were detectable for anti-rEno1 in 98.3% (59/60) of participants
with system candidiasis, for anti-rBgl2 in 95.0% (57/60), and
for anti-rPgk1 in 89.8 ∼ 91.5% (53 ∼ 54/59). In this study,
we got similar results (Table 3) and the sensitivity, specificity,
positive, and negative predictive values were 88.5, 90.0, 90.2, and
88.2% for anti-rEno1 detection, 86.5, 92.0, 91.8, and 86.8% for
anti-rPgk1 detection and 80.8, 90.0, 89.4, and 81.8% for anti-
rBgl2 detection, respectively. Though obtaining multiple samples
might increase the sensitivity, specificity, PPV, andNPV (Odabasi
et al., 2004), we got remarkable results here based on single
sample protocol according to which the serum samples were
obtained retrospectively within 24 h after positive culture results.
This indicates that the factors affecting the clinical performance
of serological diagnostic tests are not only how to obtain the
samples, but also when. Use of combinations of the ELISAs
were recommended by some researchers, but the data (not
shown) we got didn’t show increased ability to detect infection in
participants with IC when two or three ELISAs were combined,
whichmight be attributed to the fact that the performance of each
assay was remarkable enough.
IgG antibodies against rEno1, rPgk1, and rBgl2 can be
detected in the serum of SC mice. The kinetics of antibodies
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FIGURE 4 | Antibody levels and titers in study patients. The levels of anti-rEno1 (A), anti-rPgk1 (B), and anti-rBgl2 (C) in human sera were determined by ELISA
and human sera were pre-diluted before detection (1:400 for rEno1, 1:200 for rPgk1, and 1:100 for rBgl2). The levels of anti-rEno1, anti-rPgk1 and anti-rBgl2 in
proven IC patients were higher than control group. (D) Ln antibody titers in proven IC patients. Anti-rEno1 antibody possesses the highest titer, followed by rPgk1 and
rBgl2. Each symbol represents antibody level (or titer in D) of individual human serum. The horizontal lines indicate the mean ± SEM for each group. Means were
compared by Students t-test: **P < 0.001, *P = 0.001.
TABLE 3 | Sensitivity, specificity, and predictive values for the detection of
anti-rEno1, anti-rPgk1 and anti-rBgl2a.
Cutoff Sensitivity, specificity, PPVb, NPVc,
value % % % %
Anti-rEno1 0.436 88.5 90.0 90.2 88.2
Anti-rPgk1 0.537 86.5 92.0 91.8 86.8
Anti-rBgl2 0.529 80.8 90.0 89.4 81.8
aResults are calculated per patient according to the results of an analysis of 52 serum
samples from 52 proven IC patients and 50 serum samples from 50 controls;
bPPV, positive predictive value;
cNPV, negative predictive value.
against each recombinant antigen in the same model is different,
which can be directly observed by immunoblotting and validated
by titer determination of positive sera from proven IC patients.
These results indicate that recombinant Eno1, Bgl2, and Pgk1 are
different at the immunoreactivity with sera from SC mice or IC
patients, even though they are effective immunogenes. Reasons
for this complication may be: (1) Recombinant proteins cannot
be fully equal to the natural ones and potential epitopes could
be lost due to miss folding or a lack of correct post-translational
modification, both of which may affect the conformational
structure of the native protein. In support of this, Mochon
TABLE 4 | IgG antibodies and microbiological surveillance of proven IC
patients.
Pathogen n No. (%) positive
Anti-rEno1 Anti-rPgk1 Anti-rBgl2
C. albicans 22 20 (90.1) 20 (90.1) 21 (95.5)
C. tropicalisa 9 8 (88.9) 7 (77.8) 6 (66.7)
C. parapsilosisa 9 8 (88.9) 7 (77.8) 8 (88.9)
C. glabrata 7 6 (85.7) 7 (100) 5 (71.4)
C. lusitaniae 2 2 (100) 1 (50.0) 1 (50.0)
C. krusei 3 2 (66.7) 3 (100) 1(33.3)
C. guilliermondii 1 1 (100) 1 (100) 1 (100)
Total 53 47 (88.7) 46 (86.8) 43 (81.1)
aone patient was confirmed to be infected with two Candida species of C. tropicalis and
C. parapsilosis.
et al. (2010) reported antigenicity of in vitro expressed Bgl2
without any glycosylation was likely to be different from the Bgl2
produced by C. albicans used in the 2D-PAGE immunoblots.
(2) The immunogenicity for Eno1, Pgk1, and Bgl2 might be
different in the Candida infected hosts; (3) Host serological
response to pathogen antigen is limited by the range in protein
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abundance, and the abundances of Eno1, Pgk1, and Bgl2 are
different in the cell wall of C. albicans. Enolase is one of the most
abundant proteins inC. albicans (Sundstrom and Aliaga, 1992) as
it accounts for about 0.7% of the total protein content of yeast and
about 2% of hypha (Sundstrom et al., 1994). Better knowledge
of serological response to different recombinant antigens is
useful to develop a peptide or DNA vaccine against C. albicans
and to identify selective serological diagnostic reagents. In this
study, high serological response of recombinant Eno1 makes it
possible to develop more sensitive and quantitative IgG detection
methods in clinical practice for IC serodiagnosis. According to
themurinemodel experimental data, high antibody levels remain
after organ fungal burdens become undetectable. This might
mean that patients would be tested as positive after successful
anti-fungal treatment and we will further investigate how the
serological profile changes during the treatment in the future.
Establishment of suitable animal model is one of the
critical means of pathogenic biological research. To generate a
murine model of SC, the researchers mostly employ intravenous
inoculation (Louie et al., 1998; MacCallum, 2009). In this study,
we injected C. albicans SC5314 into the peritoneal cavity of
cyclophosphamide preconditioned immunocompromised mice
to cause systemic infection. For a BALB/c mouse with 18 ∼
20 g body weight, the challenging dose is about 1 × 106 CFU.
A dose of 1 × 107 CFU/mouse for intraperitoneal inoculation
would kill the mice in 3 days according to our experimental
data (not shown). Compared with the intravenous injection
model, the intraperitoneal injection model has the advantage
of easy operation. Besides successful systemic infection and
immune challenge, a low dose of C. albicans challenge model
(1 × 106 CFU/mouse, i.p.) has no fatal damage to the mice and
is suitable for serological studies that need relatively long-term
observation.
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